- Clinical-stage biotech Atossa Therapeutics ( NASDAQ: ATOS ) announced Monday that the U.S. regulators issued a new patent related to its formulation of (Z)-endoxifen, which forms its lead clinical program.
- Atossa ( ATOS ) is experimenting with an oral formulation of (Z)-endoxifen, which, according to the company, is the most active compound in the FDA-approved breast cancer therapy tamoxifen.
- Studies are currently underway for its (Z)-endoxifen formulation in healthy women with measurable breast density and premenopausal women with ER+/HER2- breast cancer.
- The new patent (No. 11,572,334) "ensures that in the U.S., Atossa will have the only (Z)-endoxifen treatment delivered orally with an enteric capsule, which we believe is the optimal way to deliver the drug," Steven Quay, Chief Executive of Atossa ( ATOS ) said.
- Seeking Alpha contributor, Bret Jensen issued a Hold rating on Atossa ( ATOS ) in October, arguing that the company has an issue with its investor relations department. "If the company doesn't have an investor relations head, they dearly need to fill that position," he urged at the time.
For further details see:
Atossa announces new U.S. patent covering lead asset